Document Detail

Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
MedLine Citation:
PMID:  22149523     Owner:  NLM     Status:  MEDLINE    
β-Blockers are a standard of care in many clinical settings such as acute myocardial infarction, heart failure and patients at risk for a coronary event. However, not all β-blockers are the same and they vary in properties such as lipophilicity, metabolic profile, receptor inhibition, hemodynamics, tolerability and antioxidant/anti-inflammatory effects. It has been unclear whether these differences affect outcomes or if one β-blocker should be preferred over another. This review will summarize the properties of metoprolol, atenolol and carvedilol, as well as comparative experimental and clinical trials between these agents. We will provide compelling evidence of why carvedilol should be a first-line β-blocker and why it offers many advantages over the β1-selective β-blockers.
James J DiNicolantonio; Daniel G Hackam
Related Documents :
23723253 - Effects of cell grafting on coronary remodeling after myocardial infarction.
7144223 - Thrombectomy: surgical treatment of the thrombosed björk-shiley prosthesis. report of ...
8334373 - Coronary angioplasty for acute myocardial infarction in a hospital without cardiac surg...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  10     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-13     Completed Date:  2012-04-23     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  13-25     Citation Subset:  IM    
Wegmans Pharmacy, 500 South Meadow Street, Ithaca, NY 14850, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / adverse effects,  pharmacokinetics,  therapeutic use*
Antihypertensive Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Atenolol / adverse effects,  pharmacokinetics,  therapeutic use
Biological Markers / blood
Carbazoles / adverse effects,  pharmacokinetics,  therapeutic use*
Hypertension / blood,  drug therapy*,  metabolism,  physiopathology
Metoprolol / adverse effects,  pharmacokinetics,  therapeutic use
Myocardial Infarction / etiology,  prevention & control
Propanolamines / adverse effects,  pharmacokinetics,  therapeutic use*
Recurrence / prevention & control
Sympathetic Nervous System / drug effects
Vasodilator Agents / adverse effects,  pharmacokinetics,  therapeutic use
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Biological Markers; 0/Carbazoles; 0/Propanolamines; 0/Vasodilator Agents; 0K47UL67F2/carvedilol; 29122-68-7/Atenolol; 37350-58-6/Metoprolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antioxidant and anticholinesterase effects of frequently consumed cereal grains using in vitro test ...
Next Document:  Understanding the genetics of coronary artery disease through the lens of noninvasive imaging.